Peter Hébert

Who they are

Peter Hébert is Co-Founder and Managing Partner at Lux Capital — he also co-founded Lux Research as a spin-off in 2003 and served as its founding CEO, and funded the StartNow entrepreneurship series at Syracuse's Newhouse School.

Person

Peter co-founded Lux Capital in 2000 from scratch, before deep science investing had a name — the firm now manages approximately $4 billion in assets. He came out of Syracuse University's Newhouse School, graduating cum laude in 1999 as a Chancellor's Scholar in communications, then went straight into equity research at Lehman Brothers before pivoting to venture. The arc is: media school → Wall Street analyst → firm builder, with the founding instinct running all the way through. Inside Lux he conceived and built companies outright: Lux Research (a technology research advisory firm he ran as founding CEO until 2008), Kurion (nuclear waste remediation), and Variant Bio (rare genetics). On the philanthropic side he co-founded Young Wall Street, serves on the board of the Boys & Girls Club of the Peninsula, mentors at Imagine K12, and funded the StartNow series at Newhouse. He writes on Medium via the Lux Capital publication — themes include conviction, deep science investing, and what grit looks like in founders — and posts actively on LinkedIn; he's also a regular on CNBC and Bloomberg TV and has lectured at Columbia, Cornell, MIT, Stanford, and Yale. Possibly — the Newhouse communications background shapes how he talks about hard science to non-technical audiences, which may explain why he shows up as a media commentator more than most deep-tech VCs.

Company

Lux Capital is a deep science venture firm Peter co-founded in 2000 with approximately $4 billion in assets under management today. The firm's model goes beyond writing checks — it conceives and builds companies internally, with Kurion (nuclear waste remediation), Variant Bio (rare genetics), and Lux Research among the in-house creations. Peter has been publicly vocal about federal research funding cuts, a live tension for a firm whose portfolio depends on the science infrastructure that government grants sustain. Possibly — a keynote at LSI USA '26 signals Lux is active in the medtech and health-adjacent defense conversation.

Market

Lux sits in the deep science and hard-tech venture segment alongside firms like Founders Fund and Breakthrough Energy Ventures, differentiating on a model where the firm conceives companies rather than just funding them. The portfolio spans nuclear remediation, advanced materials, autonomous systems, and rare genetics — sectors where long development cycles and capital intensity thin the competitive field. Current industry dynamics include pressure from federal research funding cuts, which Peter has addressed publicly, and growing investor interest in defense and autonomous technologies.

Network

Peter's closest professional anchor is Josh Wolfe, his co-founder and co-Managing Partner at Lux Capital. Robert Paull is also listed as a Lux co-founder. Outside Lux, his network touches early-stage VC through Jake Saper at Emergence Capital and Chad Byers and Pratyush Buddiga at Susa Ventures.

Josh Wolfe· Co-Founder and Managing Partner, Lux Capital
Robert Paull· Co-Founder, Lux Capital
Jake Saper· Partner, Emergence Capital
Chad Byers· Partner, Susa Ventures
Pratyush Buddiga· Partner, Susa Ventures

How they likely show up

Founded Lux Capital in 2000 and has run it for over two decades → thinks in decade-long conviction arcs, not fund cycles.
Internally conceived and built companies like Kurion and Variant Bio rather than just sourcing deals → prefers principal roles over pure capital allocation; likely engages operationally with founders.
Communications degree from Newhouse before Wall Street before VC → probably translates technical complexity into plain language as a deliberate skill, not an afterthought.
Active on LinkedIn, Medium, CNBC, and Bloomberg TV → comfortable being visible and on record; likely responds well to substantive pushback on ideas.
Funded the StartNow series at his own alma mater and mentors at Imagine K12 → institution-builder instinct extends beyond the firm; values long feedback loops over transactional relationships.
Publicly vocal on federal research funding cuts → willing to take positions that could create friction with government stakeholders, signals that conviction matters more to him than political comfort.

Conversation tips

→ Reference a specific Medium piece or LinkedIn post — he writes with genuine conviction on deep science investing and will know immediately whether you've read him.
→ Ask about the in-house company-building model (Kurion, Variant Bio) rather than treating Lux as a conventional fund — that's what distinguishes the firm and where he'll have the most to say.
→ Come with a view on federal research funding dynamics; he's been public about the risk funding cuts pose to the science ecosystem and will engage hard on anyone who has thought it through.
→ His Syracuse Newhouse background is a genuine point of pride (Chancellor's Scholar, funded the StartNow program) — worth acknowledging if the conversation allows, but only if you know a specific detail.

Toolbox

Openers

Open on the in-house company conception model — he built Kurion from scratch inside Lux to handle nuclear waste remediation, which is a fundamentally different posture than sourcing deals. Ask how that model has evolved over 25 years.
Reference his Medium essay on conviction — he's written directly about what conviction means in deep science investing, and leading with a specific argument from that piece signals you did more than skim his bio.
Mention the federal research funding cuts issue — he's been publicly critical of cuts to science infrastructure and it's a live topic that touches his portfolio directly; it's a fast route to a substantive conversation.

Discovery questions

When Lux conceives a company like Kurion or Variant Bio internally, how do you decide when to hand the operational reins to an outside CEO versus keep it closer to the firm?
You came out of Newhouse in communications before Lehman, before VC — how much does that media training shape how you evaluate founders pitching in technical domains you can't fully diligence yourself?
With approximately $4 billion under management and a thesis that depends on long-cycle science, how are you thinking about the compounding effect of federal research funding cuts on the companies Lux will want to fund five years from now?

Avoid

Don't treat Lux as a conventional check-writing fund — the in-house company-building model is central to Peter's identity and glossing over it will signal you haven't done the work.

Make it yours